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Abstract  
Formulation optimization and antidotal combination therapy are the two important tools 
to enhance the antidotal protection of the cyanide (CN) antidote dimethyl trisulfide 
(DMTS). The focus of this study is to demonstrate how the formulation with polysorbate 
80 (Poly80), an excipient  used in pharmaceutical technology, and the combinations 
with other CN antidotes having different mechanisms of action enhance the antidotal 
efficacy of the unformulated (neat) DMTS. The LD50 for CN was determined by the 
statistical Dixon up-and-down method on mice. Antidotal efficacy was expressed as 
antidotal potency ratio (APR). CN was injected subcutaneously one minute prior to  the 
antidotes’ injection intramuscularly. The APR values of 1.17 (dose: 25 mg/kg 
bodyweight) and 1.45 (dose: 50 mg/kg bodyweight) of the neat DMTS were significantly 
enhanced by the Poly80 formulation at both investigated doses to 2.03 and 2.33, 
respectively. The combination partners for the Poly80 formulated DMTS (DMTS-Poly80; 
25 and 50 mg/kg bodyweight) were 4-nitrocobinamide (4NCbi) (20 mg/kg bodyweight) 
and aquohydroxocobinamide (AHCbi; 50, 100 and 250 mg/kg bodyweight). When 
DMTS-Poly80 (25 and 50 mg/kg bodyweight; APR=2.03 and 2.33 respectively) was 
combined with 4NCbi (20 mg/kg bodyweight; APR=1.35), significant increase in the 
APR values were noted at both DMTS doses (APR=2.38 and 3.12 respectively). AHCbi 
enhanced the APR of DMTS-Poly80 (100 mg/kg bodyweight; APR=3.29) significantly 
only at the dose of 250 mg/kg bodyweight (APR=5.86). These studies provided 
evidence for the importance of the formulation with Poly80 and the combinations with 
cobinamide derivatives with different mechanisms of action for DMTS as a CN antidote 
candidate.  
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Abbreviations 
APR   Antidotal potency ratio 
CN           Cyanide (as CN- and/or HCN) 
DMTS   Dimethyl trisulfide 
MetHb  Methemoglobin 
Poly80   Polysorbate 80 
DMTS-Poly80 Polysorbate 80 formulated DMTS 
Cbi    Cobinamide 
AHCbi   Aquohydroxocobinamide  
4NCbi 4-Nitrocobinamide [(Cbi(NO2)2 + 2 eqv. NO2 ] or  
[(Cbi(NO2)4)]  
DNCbi     Dinitrocobinamide [Cbi(NO2)2] 
CI   95% Confidence interval 
SD  Standard deviation 
SEM  Standard error of mean 
            IM                               Intramuscular Ac
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Introduction 
Cyanide (CN), representing both CN- and HCN inclusively, inhibits the Cytochrome c 
Oxidase, the terminal oxidase of the mitochondrial electron transport chain, thereby 
suppressing cellular oxygen utilization and aerobic ATP production (Vogel et al., 1981; 
Way et al., 1988). The heart and the brain are the most susceptible organs to CN 
poisoning due to their high ATP demand. The two current FDA-approved CN therapies in 
the United States are Cyanokit® (Borron et al., 2006; Zakharov et al., 2015) and 
NithiodoteTM (Scottsdale, 2011). Cyanokit® contains hydroxocobalamin, which acts as a 
CN scavenger. NithiodoteTM is a combination of sodium thiosulfate (acting as a sulfur 
donor to convert CN to the less toxic thiocyanate) and sodium nitrite (primarily acting as 
a methemoglobin (MetHb) former to scavenge CN). Recent research revealed its other 
role of nitric oxide formation (Kanai et al., 2001). Both CN therapies have undesirable 
side effects, require large injection volumes during intravenous administration and are 
unsuitable for a mass casualty scenario (Marraffa et al., 2012). Furthermore, thiosulfate 
is dependent on the endogenous mitochondrial Rhodanese and has a limited cell 
penetrating capability and moderate chemical reactivity with CN to form thiocyanate 
(Rockwood et al., 2016; Schulz, 1984; Way et al., 1988). Additionally, overdosing nitrite 
can cause methemoglobinemia (Schulz, 1984; Way et al., 1988). These problems led to 
a search for improved countermeasures that would also guarantee rapid and easy 
administration, such as intramuscular (IM) injection.  
One of the recent results of research efforts was the discovery of dimethyl trisulfide 
(DMTS) as the “Advanced Sulfur Donor” (Rockwood et al., 2016). DMTS is present in 
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many natural sources, such as cabbage (Brassica oleracea var. capitate), broccoli 
(Brassica oleracea var. italic) cauliflower (Brassica oleracea var. botrytis), 
 but it is present in the highest amounts in garlic (Allium sativum); each garlic bulb has 
15-19 µg DMTS (Block, 1985).  Studies have shown that DMTS has significantly higher 
in vitro sulfur donor reactivity and in vivo antidotal efficacy than the present therapy, 
thiosulfate (DeLeon et al., 2018; Kiss et al., 2017; Rockwood et al., 2016). When 
formulations were investigated, the goal was to find a formulation that provides fast 
absorption with high cmax and good antidotal protection after IM administration. Early 
attempts with formulations led to the lipid based micellar encapsulation of DMTS with 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine N-[methoxy-(polyethylene glycol)-
2000] (PEG2000-DSPE) that provided remarkable antidotal protection at relatively low 
dose; however, its limited stability did not support further studies (Kovacs et al., 2016b). 
Further attention was focused on the DMTS formulation with the FDA-approved 
surfactant, polysorbate 80 (Poly80) (Kovacs et al., 2016a). The 15% Poly80 formulation 
provided the advantages of good absorption kinetics (Kiss et al., 2017), and high 
antidotal efficacy (Kovacs et al., 2016a). Pharmacokinetic studies demonstrated that the 
Poly80-formulated DMTS was rapidly absorbed (within 5-15 min) after IM administration 
(Kiss et al., 2017) and that the intravascular residence time was reasonable (elimination 
half-life = 36 min) (De Silva et al., 2016).  
The shortcoming of the Poly80-formulated DMTS, namely the large injection volume 
extrapolated for humans -due to the limited solubility of DMTS in Poly80 (75mg/ml)-, 
initiated further efforts to develop new, optimized formulations, and/or combinations with 
other CN countermeasures having different mechanisms of action. The combination 
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approach is also advantageous as it reduces the side effects (toxic effects) of each 
component.   
Cobinamide is a cobalamin derivative, which has the advantage of allowing two CNs to 
bind to the cobalt ion of the Corrine ring (Lee et al., 2016). Cobinamide is 3-10 times 
more potent than hydroxocobalamin in mouse, rabbit, and swine models (Chan et al., 
2015; Chan et al., 2018; Cronican et al., 2018). It is reported that nitrocobinamide 
derivatives are very stable and are absorbed well after IM injection (Chan et al., 2015).  
This study reports the antidotal effects of the neat DMTS in comparison with the Poly80-
formulated DMTS (DMTS-Poly80) at the doses of 25 mg/kg bodyweight and 50 mg/kg 
bodyweight. To surpass the shortcomings of the DMTS-Poly80 alone, namely the 
required high injection volume due to the limited DMTS solubility, combination studies 
with two Cbi derivatives (4-nitrocobinamide, 4NCbi and aquohydroxocobinamide, AHCbi) 
were explored. The structures of these Cbi derivatives and the nomenclature of the 
4NCbi were explained in earlier publications (Chan et al., 2015; Lee et al., 2016). Briefly, 
the 4NCbi is a combination itself. It consists of 1 eqv. Dinitrocobinamide (DNCbi) with 
two nitro groups attached to the cobalt ion in the Corrine ring, plus 2 eqv. of nitrite. To 
simplify the nomenclature we call this combination 4NCbi. The combination of DMTS 
with Cbi derivatives represents one of the efforts to reduce the DMTS injection volume 
and dose while still achieving good antidotal protection. Formulation optimization, the 
other  component of this effort, is part of the ongoing studies and will be published later.    Ac
ce
pte
d M
nu
scr
ipt
  
Materials and Methods 
Chemicals and Supplies for Animal Studies 
All chemicals were of the highest purity commercially available. DMTS (C2H6S3, CAS: 
3658-80-8; ≥96%),  and Potassium cyanide (KCN, CAS:151-50-8; ≥ 98% ) were 
purchased from Sigma Aldrich (St. Louis, MO, USA). Poly80 (Polysorbate 80, 
C32H60O10, CAS: 9005-65-6, ≥95%) was purchased from Alfa Aesar (Haverhill, MA, 
USA). Dinitrocobinamide and aquohydroxocobinamide, (cobalt(3+);3-
[(1~{R},2~{S},3~{S},5~{Z},7~{S},8~{S},10~{Z},13~{S},15~{Z},17~{R},18~{R},19~{R})-
2,7,18-tris(2-amino-2-oxoethyl)-3,13-bis(3-amino-3-oxopropyl)-17-[3-[[(2~{R})-2-
hydroxypropyl]amino]-3-oxopropyl]-1,2,5,7,12,12,15,17-octamethyl-8,13,18,19-
tetrahydro-3~{H}-corrin-24-id-8-yl]propanamide, C48H72CoN11O8
+2, CAS:13497-85-
3) were prepared at UCLA (Broderick et al., 2005), and the purity of  both was 
>95% by HPLC from hydroxo-cobalamin (OH-Cbi, Sigma Chemical Co”). Hamilton 
Luer-lock syringes (VWR International, Suwanee, GA, USA) with volumes of 50, 100 
and 250 µL were used for IM (27G, ½ inch needles) and subcutaneous injections (25G, 
1 inch needles) in the animal studies.  
 
Animals 
Animal studies were conducted using healthy male CD-1 mice (18–20 g; Charles River 
Breeding Laboratories, Inc., Wilmington, Massachusetts and SHSU Animal Facility, 
Huntsville, Texas). Animal procedures were conducted in accordance with the 
guidelines by The Guide for the Care and Use of Laboratory Animals (National 
Academic Press, 2010), accredited by AAALAC (American Association for the 
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Assessment and Accreditation of Laboratory Animal Care, International). The mice were 
fed with Zeigler Rodent RQ 18-6 diet (Zeigler Bros. Inc., Gardners, PA, USA) and water 
ad libitum, and were housed at 21 °C in light-controlled rooms (12 h light/dark, full-
spectrum lighting cycle with no twilight). At the termination of the experiments, animals 
were euthanized in accordance with the AVMA Guidelines for the Euthanasia of 
Animals: 2013 Edition (AVMA Guidelines). At Sam Houston State University, the 
Institutional Animal Care and Use Committee (IACUC) permission number is 15-09-14-
1015. 
 
Solutions and Formulations 
KCN Solutions-   
20 mg/ml KCN was created by adding 500 mg KCN and D.I water in a 25 ml volumetric 
flask, and  the solution was vortexed until  the obvious crystals were dissolved.  KCN 
(7.5 mg/ml) was prepared by adding 8.33 ml of D.I water to 5 ml of the 20 mg/ml KCN 
solution, and was vortexed for 5 min. KCN (5 mg/ml) was made by adding 15 ml of D.I 
water to 5 ml of the 20 mg/ml KCN solution, and was vortexed for 5 min. KCN (2.5 
mg/ml) was created by adding 21 ml of D.I. water to 3 ml of the 20 mg/ml KCN solution, 
and was vortexed for 5 min. 
15% Poly80-formulated DMTS- 
This formulation was prepared as previously described (Kovacs et al., 2016a). Briefly, 
First the 15% (w/w) Poly80 was prepared by dissolving 7.50 g Poly80 in 42.5 g of D.I 
water. It was vortexed for 5 min, then auto-vortexed for 30 minutes. The solution was 
kept in the refrigerator overnight before use. To prepare 25 ml of 50 mg/ml  DMTS in 
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15% (w/w) Poly80 solution, 1.25 g DMTS was added to the 15% (w/w) Poly80 solution 
in a 25 ml volumetric flask, and hand-vortexed for 5 min. The solution was then vortexed 
for 30 min by an auto-vortexer (Heidolph Multi Reax) and was placed into glass vials for 
storage and crimped to be tightly sealed. 
Solutions for the DMTS and Cbi combination studies 
4NCbi injection  solution [40mg/ml]. 13.92 mg NaNO2 was dissolved in 3 ml of 15% 
Poly80 solution, then 71.792 mg DNCbi was added, and the solution was vortexed for 5 
min.    AHCbi in water [125 mg/m]): was prepared for the AHCbi administration by 
dissolving AHCbi in water.  
 
In vivo Experiments 
Male CD-1 mice (18-20g) received the antidote solutions IM one minute after the KCN 
solution subcutaneously. The LD50 and 95% confidence interval values were determined 
by the simulated up-and-down method (Dixon, 1965; Dixon & Massey, 1983; Bruce, 
1985). USAMRICD provided a Microsoft Office Excel sheet that utilizes the equations 
from these methods to calculate the dose of CN to apply for each stage. 
General Method for Antidotal Efficacy Studies: In the therapeutic antidotal efficacy 
experiments, CN was injected subcutaneously one minute prior to  the antidotes 
injection intramuscularly, and the injection volume was calculated based on the dose, 
the animal weight, and the stock solution concentrations according to the following 
formula: Injection volume (µl) = animal weight (g) X dose (mg/kg bodyweight) / stock 
concentration (mg/ml). Each study, regardless of the number of treatment groups, 
contained a control group with KCN injection only, without antidote. After the injection of 
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KCN and the antidote(s), the animals were kept in observation cages for two hours to 
monitor survival. Surviving animals were further observed for 24 hours, but based on 
our experience, if the animal is going to die, it does so within 2 hours post-KCN 
injection. Animals were declared dead if the following criteria were met: breathing 
stopped and no heart beat was detected (followed by the flipping from supine position to 
a prone position in most cases). The starting dose of KCN for the control was 10 mg/kg 
bodyweight. The starting KCN doses for the different test groups were chosen based on 
pilot experiments.  If the antidote was expected to provide good protection, the starting 
dose of KCN for the group was higher (e.g. 30-40 mg/kg bodyweight). The dose of the 
test antidote solution was constant for each test group, and the injection volume was 
calculated based on the above formula what includes the weight of the animal, the 
dose, and the concentration of the test solution. The formulation concentration for the 
antidotes were: DMTS=50 mg/ml in Poly80; 4NCbi=40 mg/ml in Poly80; AHCbi=125 
mg/ml in water. The injection sites: DMTS alone was injected IM into the upper part 
(thigh) of one of the back legs; combinations of antidotes (DMTS and 4NCbi or AHCbi) 
were injected into the thigh of the two separate back legs, and the CN solution was 
injected subcutaneously (under the skin at the back part of the neck). The KCN dose for 
each stage varied within the group depending on instructions given by the software.  To 
keep the KCN injection volume within the range of 80-120 µl, the concentration of KCN 
solutions varied (2.5 mg/ml, 5.0 mg/ml, 7.5 mg/ml) depending on the KCN dose 
administered. After adjusting the starting dose and the stage-distance (dose difference 
between stages) for each group, the software (described above) provided information 
on the dose for the next stage. Based on the slopes of the log dose-response curves 
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determined in earlier cyanide studies (Petrikovics et al., 1994) by the classic Litchfield-
Wilcoxon method (Litchfield and Wilcoxon, 1949), the log dose difference was set as 0.1 
for all groups in the program. After injection, based on the result of the observation, 
(alive or dead), the next stage was determined by the software: If the animal died, the 
next stage had lower KCN dose, if the animal survived, the next stage had higher KCN 
dose.  
When the stopping condition has been met, the program determined the LD50 values 
with 95% confidence limits. In the up-and-down method 10-18 mice were used for each 
LD50 determination. In each group, the number of stages/animals depended on how 
close the starting dose was to the expected LD50 value (Bruce, 1985; Efron, 1979). The 
APR values were expressed as the ratio of the LD50 estimate of KCN with the 
antagonist(s) and the LD50 estimate of KCN without antidote (control).  
 
Statistical Analysis 
The APR values of the treatment groups in figures were compared by applying 
statistical analysis with GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, 
California). In case of testing the effect of neat vs. Poly80 formulated DMTS and the 
effect of 25 vs. 50 mg/kg bodyweight doses of DMTS two-way ANOVA was used with 
Bonferroni posttest. For evaluating the effect of different combinations of DMTS and 
4NCbi or AHCbi separated treatment groups were compared with Student t-test or one-
way ANOVA followed by Dunnett’s Multiple Comparison Test. Each comparison is 
specified in the description of figures. Changes were considered statistically significant 
at p < 0.01. 
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With the Dixon up-and-down method, the LD50 doses with the estimated 95% 
confidence intervals (CI) for DMTS were calculated using software algorithms described 
in “Implementation of Dixon & Massey UDP,” Introduction to Statistical Analysis, 1983, 
pp 434–438.   
 
Results 
CN antidotal protection of DMTS alone (neat and Poly80 formulated) and in 
combinations with two Cbi derivatives (4NCbi and AHCbi) are presented. The antidotal 
efficacy was expressed as APR, where APR is the ratio of LD50 of CN in the presence of 
the antidote and the LD50 of CN without the antidote (control).  
 
 
Figure 1. The antidotal effect (APR) of neat DMTS vs. DMTS-Poly80 against CN 
intoxication in mice. The APR values are presented as means ± SD (n = 5-13). 
Statistical analysis: Two-way ANOVA followed by Bonferroni posttest. Statistically 
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significant differences (**, P < 0.01) were detected between the neat DMTS and Poly80-
DMTS at 25 and 50 mg/kg bodyweight doses.  
The mean LD50 of the related control (KCN alone treatment) for the experiments with 
neat DMTS was 7.79 (95% CI was 5.66-10.72). The mean LD50 of related control (KCN 
alone treatment) for the experiments with DMTS-Poly80 was 6.78 (95% CI was 5.41-
8.49). 
 
Figure 1. shows the APR values of neat DMTS vs. the DMTS-Poly80 at  DMTS doses of 
25 and 50 mg/kg bodyweight.  Without the Poly80-formulation, the neat DMTS showed 
unremarkable protection at the investigated doses, however, the APR values of 1.17 
(dose: 25 mg/kg bodyweight) and 1.45 (dose: 50 mg/kg bodyweight) of the neat DMTS 
were significantly enhanced (p=0.0024) by the Poly80 formulation. The enhanced APR 
values for the Poly80-DMTS were 2.03 and 2.33 at the doses of 25 and 50 mg/kg 
bodyweight, respectively.  
. In order to enhance the antidotal efficacy, and reducing the side effects, combinations 
of DMTS-Poly80 with Cbi derivatives were explored.   
  
Ac
ce
pte
d M
an
us
cri
pt
  
Table 1. Cyanide LD50 values and CN antidotal protections with DMTS-Poly80 + 4NCbi 
combinations.  
Experi-
ments 
Treatment 
a
 n 
b
 LD50 (mg KCN/kg) 
(95% CI) 
c
 
APR (mean) ± SD 
(related control)
d
 
1-1 KCN alone 
(Control A) 
12 6.17 
(4.94-7.75) 
1.00 ± 0.40 
1-2 KCN alone 
(Control B) 
8 6.78 
(5.41-8.49) 
1.00 ± 0.33 
1-3 KCN alone 
(Control C) 
15 8.91 
(7.55-10.50) 
1.00 ± 0.33 
1-4 KCN + 
4NCbi (20 mg/kg) 
9 8.32 
(6.25-11.06) 
1.35 ± 0.60 
(Control A) 
1-5 KCN + DMTS (25 mg/kg) 9 13.73 
(11.10-16.99) 
2.03 ± 0.67 
(Control B) 
1-6 KCN + DMTS (50 mg/kg) 13 15.78 
(13.22-18.84) 
2.33 ± 0.76 
(Control B) 
1-7 KCN + 4NCbi (20 mg/kg) + 
DMTS (25 mg/kg) 
9 21.20 
(17.14-26.23) 
2.38 ± 0.78 
(Control C) 
1-8 KCN + 4NCbi (20 mg/kg) + 
DMTS (50 mg/kg) 
10 27.75 
(22.43-34.33) 
3.12 ± 1.08 
(Control C) 
 
aThe aqueous KCN solutions were injected subcutaneously, and the antidotes were 
injected intramuscularly. The injection solution of 50 mg/ml DMTS in Poly80 was used for 
the DMTS-Poly80 administrations. The injection solution of 40 mg/ml 4NCbi in Poly80 was 
used for the 4NCbi administrations. When DMTS-Poly80 and 4NCbi were administered in 
combination, they were injected into separate legs. The injection volume was calculated 
based on the stock solution concentration, the dose, and the weight of the animals. 
bn represents the number of animals used in each experiments.  
cThe LD50 values were determined by the up-and-down method (Dixon, 1965) and 
expressed as mean +/- 95% confidence limits.   
dThe APR values were calculated as LD50 of CN with the antidotes / LD50 of CN without 
antidote (control). For each experimental setup, a control group was included. 
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Figure 2. Cyanide antidotal protections (APR) with DMTS-Poly80 alone and in 
combinations with 4NCbi when the 4NCbi dose was constant and the DMTS doses 
varied. Groups: 1 - 4NCbi (20 mg/kg); 2 – DMTS (25 mg/kg); 3 – DMTS (50 mg/kg); 4 – 
[DMTS (25 mg/kg) + 4NCbi (20 mg/kg)]; 5 – [DMTS (50 mg/kg) + 4NCbi (20 mg/kg)]. 
APR values are presented as means ± SD (n = 8-15). Statistical analysis: ANOVA 
followed by Dunnet’s Multiple Comparison Test. Statistical significance calculations 
were performed between Group 4 vs. Group 1 and Group 2; Group 5 vs. Group 1 and 
Group 3. Significant difference was detected when Group 4 was compared to Group 1 
(**, P < 0.01), and when Group 5 was compared to Group 1 (***, P< 0.001). 
 
Figure 2. (from Table 1. data) shows the APR values for DMTS-Poly80 used in 
combination with 4NCbi. The 4NCbi dose was constant (20 mg/kg), and the dose of 
DMTS in 15% Poly80 varied (25 mg/kg and 50 mg/kg). Each time, the antidotes were 
injected IM one minute after CN injection.  For the statistical comparison, the antidotal 
effect (APR) of DMTS-Poly80 and 4NCbi combinations were compared to the 
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corresponding doses of the compounds alone. DMTS-Poly80 in the doses of 25 and 50 
mg/kg significantly (p<0.01) elevated the antidotal effect of 4NCbi in 20 mg/kg dose 
(Group 4 vs. Group 1; or Group 5 vs. Group 1). The presence of 4NCbi (20 mg/kg) 
enhanced the antidotal protection of DMTS-Poly80 alone at the investigated doses of 25 
and 50 mg/kg (Group 5 vs. Group 3; or Group 4 vs. Group 2), however this increase 
was not significant. 
 
Table 2. Cyanide LD50 values and CN antidotal protections with DMTS-Poly80 + AHCbi 
combinations. 
Experi-
ments 
Treatment
a
 n
b
 
LD50 (mg KCN/kg 
(95% CI)
c
 
APR (mean) ± SD 
(related control)
d
 
2-1 
KCN alone 
(Control D) 
7 
10.94 
(8.59-13.91) 
1.00 ± 0.33 
2-2 
KCN alone 
(Control E) 
8 
9.84 
(7.85-12.33) 
1.00 ± 0.33 
2-3 
KCN alone 
(Control F) 
6 
11.40 
(8.79-14.80) 
1.00 ± 0.33 
2-4 
KCN + 
AHCbi (250 mg/kg) 
9 
23.12 
(18.69-28.61) 
2.35 ± 0.77 
(Control E) 
2-5 
KCN + 
DMTS (100 mg/kg) 
8 
36.00 
(28.73-45.12) 
3.29 ± 1.08 
(Control D) 
2-6 
KCN + 
DMTS (100 mg/kg) + 
AHCbi (50 mg/kg) 
9 
41.34 
(33.42-51.14) 
3.63 ± 1.19 
(Control F) 
2-7 
KCN + 
DMTS (100 mg/kg) + 
AHCbi (100 mg/kg) 
7 
47.40 
(36.53-61.51) 
4.16 ± 1.48 
(Control F) 
2-8 
KCN + 
DMTS (100 mg/kg) + 
AHCbi (250 mg/kg) 
9 
57.66 
(46.01-72.25) 
5.86 ± 2.04 
(Control E) 
 
aThe aqueous KCN solutions were injected subcutaneously, and the antidotes were 
injected intramuscularly. The stock solution of 50 mg DMTS/ml Poly80 was used for the 
DMTS-Poly80 administrations. The stock solution of 125 mg AHCbi /ml water was used for 
the AHCbi administrations. When DMTS and AHCbi were administered in combination, 
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they were injected into separate legs. The injection volume was calculated based on the 
stock solution concentration, the dose, and the weight of the animals. 
bn represents the number of animals used in each experiments.  
cThe LD50 values were determined by the up-and-down method (Dixon, 1965) and 
expressed as mean  +/- 95% confidence limits.   
dThe APR values were calculated as LD50 of CN with the antidotes / LD50 of CN without 
antidote (control). For each experimental setup, a control group was included.  
 
 
 
 
Figure 3. Cyanide antidotal protections (APR) with DMTS-Poly80 alone and in 
combinations with AHCbi when the DMTS dose was constant, and the AHCbi doses 
varied. Groups: 1 - AHCbi (250 mg/kg); 2 – DMTS (100 mg/kg); 3 – [DMTS (100 mg/kg) 
+ AHCbi (50 mg/kg)]; 4 – [DMTS (100 mg/kg) + AHCbi (100 mg/kg)]; 5 – [DMTS (100 
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mg/kg) + AHCbi (250 mg/kg)]. APR values are presented as means ± SD (n = 7–9). 
Statistical significance calculations were performed between Group 2 vs. Group 3, 
Group 4, and Group 5 by ANOVA complemented with Dunnett’s Multiple Comparison 
Test. Student t-test were applied to check the significant differences between Group 5 
vs. Group 1. Statistically significant difference  was detected when Group 5 was 
compared to Group 1 (***, P < 0.001) and Group 2 (**, P < 0.01). 
 
Figure 3. (from Table 2. data), shows the APR values for the combinations of AHCbi + 
DMTS-Poly80 when the DMTS dose was constant (100 mg/kg) and the doses of AHCbi 
varied (50, 100 and 250 mg/kg).  For statistical calculations the effect of DMTS and 
AHCbi combinations were compared to the effect of DMTS alone. AHCbi at the doses of 
50 or 100 mg/kg did not significantly improve the antidotal effect of DMTS at the dose of 
100 mg/kg (Group 3 vs. 2 or Group 4 vs. 2). However, AHCbi at the dose of 250 mg/kg 
statistically significantly (p<0.01) enhanced the APR of DMTS (Group 2 vs. Group 5), 
and the DMTS (100 mg/kg) also significantly (p<0.001) enhanced the effect of AHCbi 
(250 mg/kg), (Group 1 vs.  Group5). 
 
Discussion and Conclusions 
This study focused on A) antidotal protection with neat DMTS vs. Poly80 formulated 
DMTS; B) antidotal protections with DMTS-Poly80 alone vs. in combinations with Cbi 
derivatives (4NCbi or AHCbi).  
To enhance the absorption of the antidote DMTS to the blood and as a consequence, to 
improve its antidotal effect and bioavailability, a well-designed, technological formulation 
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should be applied. The DMTS-Poly80 formulation with the use of the excipient Poly80, 
commonly used for drug formulation in pharmaceutical technology was intensively 
investigated and the results were published earlier (Kiss et al., 2017; Kovacs et al., 
2016a; Rockwood et al., 2016). This formulation provided the advantages of good 
absorption kinetics and high antidotal efficacy. Our studies confirmed that the Poly80 
formulation not only significantly enhanced the APR of the neat DMTS, but it also nearly 
eliminated (minimized) the tissue damage caused by the injection of DMTS without 
Poly80 (Petrikovics, unpublished data). While the APR values with the neat DMTS at 
the doses of 25  and 50 mg/kg bodyweight, and with the Poly80 formulated DMTS at the 
dose of 25 mg/kg bodyweight have never been published, the APR value for DMTS 
alone at the dose of 50 mg/kg bodyweight DMTS (Kovacs et al., 2016a) is shown here 
only for comparison.  Another alternative way to enhance the antidotal effect is the 
application of antidotal drug combinations, which can take advantage of multiple 
mechanisms of action. 
Here we report APRs obtained with DMTS in combinations with 4NCbi and AHCbi 
(Figures 2. and 3; Tables 1. and 2.). The 4NCbi (20 mg/kg bodyweight) provided an APR 
of 1.35 alone. The AHCbi alone showed remarkable antidotal effects (APR of 2.35) only 
at a higher dose (250 mg/kg bodyweight). For both combinations ([DMTS + 4NCbi] and 
[DMTS + AHCbi]) the APR values were higher than for any of the components alone, 
and in some cases the increase in the APR-values were significant.  
The mechanism of action for each component are different: the major mechanism of 
DMTS is attributed to its sulfur donor effect, when it reacts with CN and converts it to the 
less toxic thiocyanate (Schulz, 1984; Way et al., 1988). However, unlike thiosulfate, the 
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sulfur donor component of the present CN antidote therapy of NithiodoteTM, DMTS can 
convert CN to thiocyanate effectively, even without the sulfurtransferase enzyme, 
Rhodanese, but definitely less effectively than in the presence of Rhodanese. Recently 
it has been reported that DMTS can oxidize hemoglobin to MetHb (Dong et al., 2017). 
Since MetHb has high affinity to CN, MetHb can act as a scavenger (Pearce et al., 
2003; Way et al., 1988). This feature of DMTS can be considered as a minor 
mechanism for CN antidotal action. Despite the fact that nitrite, the other component of 
NithiodoteTM, is a long known and well investigated MetHb former, its capability to form 
nitric oxide recently became the focus of investigations (Kanai et al., 2001). Nitric oxide 
modulates the binding of CN to Cyt c Oxidase. On the other hand, the 4NCbi, a 
combination of 1 eqv. DNCbi + 2 eqv. of nitrite, may also act as a MetHb former, and the 
Cbi by itself is a scavenger type CN antidote (Chen, 1952).  
Our combination studies proved that the CN antidotal effects of DMTS can be enhanced 
by combining it with Cbi derivatives in a dose dependent manner. The AHCbi showed 
significant enhancement on the antidotal effect of DMTS at a higher, (250 mg/kg 
bodyweight) dose only, while the dose of 4NCbi (20 mg/kg bodyweight) was too low to 
achieve a significant enhancement on the antidotal effect of DMTS. However, from the 
side of DMTS, it significantly enhanced the APR for both 4NCbi and AHCbi at all 
investigated doses. 
Although the 15% Poly80 formulation is considered successful (Kovacs et al., 2016a), 
there are ongoing studies in our lab and our collaborating labs to develop more 
advanced formulations. These can further enhance the solubility, the bioavailability and 
the antidotal efficacy with lower DMTS doses, when applied alone. Since the solubility 
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of DMTS in the 15% Poly80 is not high enough to maintain suitable injection volumes 
for humans, investigations are focusing on advanced technological formulations with 
higher DMTS solubility. 
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